Evidence map›Paper›PMID 42234008›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2026

FAPI PET/CT in post-PCI coronary disease: in-stent restenosis characterization, MACE association, and limited short-term modulation by lipid-lowering therapy: FAPI athero trial.

Ximin Shi, Liang Wang, Haiqiong Zhang, Meiqi Wu, Chao Ren, Song Xue, Zhenhai Huang, Zhixin Hao, Zhichao Lai, Bao Liu and 4 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06280287 (PET Imaging of Fibroblast Activation in Carotid and Coronary Atherosclerotic Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06280287 unknown statusnot on this map

PET Imaging of Fibroblast Activation in Carotid and Coronary Atherosclerotic Disease

TypeobservationalSponsorPeking Union Medical College HospitalRan2021 to 2025Enrolled150ConditionsAtherosclerosisArmsFAPI PET
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ximin ShiNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Liang WangCardiology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Haiqiong ZhangNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Meiqi WuNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Chao RenNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Song XueDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Zhenhai HuangTheranostics and Translational Research Center, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhixin HaoNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Zhichao LaiVascular Surgery Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bao LiuVascular Surgery Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Zhenyu LiuCardiology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. pumch_lzy1@163.com.
Xiang LiDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. xiang.li@meduniwien.ac.at.
Li HuoNuclear Medicine Department, Peking Union Medical College Hospital, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. huoli@pumch.cn.ORCID 0000-0003-1216-083X

Funding

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-037National Natural Science Foundation of China 82302251National Natural Science Foundation of China 82472094National Natural Science Foundation of China U24A20758
6 · The paper itself

Abstract

backgroundFibroblast activation plays a key role in plaque instability and coronary artery disease (CAD) progression. In-stent restenosis (ISR) remains a major complication after percutaneous coronary intervention (PCI), increasing the risk of major adverse cardiovascular events (MACEs). This study primarily aimed to investigate whether coronary [¹⁸F]AlF-NOTA-FAPI-04 uptake is associated with major adverse cardiovascular events (MACEs) in symptomatic post-PCI patients, and secondarily to explore its ability to differentiate ISR from in-stent non-restenosis (ISnR) and to evaluate longitudinal changes under lipid-lowering therapy.

methodsIn this prospective single-centre observational cohort study, we enrolled symptomatic CAD patients with a history of PCI A total of 76 symptomatic CAD patients (30 with acute coronary syndrome [ACS] and 46 with stable coronary syndrome [SCS]) underwent FAPI PET/CT imaging. Twenty-two non-CVD individuals served as controls. Coronary SUV

resultsFAPI uptake was significantly higher in ACS (SUV

conclusionFAPI PET/CT enables non-invasive assessment of fibroblast-driven plaque activity, particularly in ISR, and identifies high-risk coronary plaques linked to MACEs. While LLT did not significantly modify fibroblast activity in the short term, further studies are needed to explore its long-term effects on plaque stability. (FAPI-PLAQUE Study, NCT06280287).

Indexed as

Coronary Artery DiseaseCoronary RestenosisFibroblast Activation Protein AlphaHypolipidemic AgentsPercutaneous Coronary InterventionPositron Emission Tomography Computed TomographyStentsAgedFemaleGelatinasesHumansMaleMiddle AgedSerine EndopeptidasesFibroblast Activation Protein AlphaGelatinasesHypolipidemic AgentsSerine EndopeptidasesCoronary artery diseaseFibroblast activation proteinIn-stent restenosisLipid-lowering therapyMajor adverse cardiovascular events

Identifiers

PMID42234008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.